Compare RVMD & STE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVMD | STE |
|---|---|---|
| Founded | 2014 | 1985 |
| Country | United States | United States |
| Employees | 883 | 3700 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2B | 22.1B |
| IPO Year | N/A | 2018 |
| Metric | RVMD | STE |
|---|---|---|
| Price | $146.92 | $213.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 5 |
| Target Price | $140.84 | ★ $275.20 |
| AVG Volume (30 Days) | ★ 3.7M | 551.6K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 1.19% |
| EPS Growth | N/A | ★ 62.73 |
| EPS | N/A | ★ 5.69 |
| Revenue | N/A | ★ $5,459,515,000.00 |
| Revenue This Year | N/A | $9.88 |
| Revenue Next Year | $533.02 | $6.32 |
| P/E Ratio | ★ N/A | $37.44 |
| Revenue Growth | N/A | ★ 6.24 |
| 52 Week Low | $34.00 | $209.61 |
| 52 Week High | $155.70 | $269.44 |
| Indicator | RVMD | STE |
|---|---|---|
| Relative Strength Index (RSI) | 63.54 | 38.68 |
| Support Level | $93.39 | $209.98 |
| Resistance Level | $152.85 | $227.10 |
| Average True Range (ATR) | 7.19 | 5.35 |
| MACD | -0.47 | -0.67 |
| Stochastic Oscillator | 61.79 | 18.67 |
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.